DOCSLIB.ORG

American Association for Cancer Research Councilors and Directors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
American Association for Cancer Research Councilors and Directors American Association for Cancer Research Councilors and Directors COUNCILORS (1907-1940) 1907 Simon Flexner, MD, PhD (1907) George W. Crile, MD (1907-08) James Ewing, MD (1907-09) Harvey P. Gaylord, MD (1907-10) Frank B. Mallory, MD (1907-11) Leo Loeb, MD (1907-12) Ernest B. Tyzzer, MD (1907-13) 1908 Gary N. Calkins, PhD (1908-14) 1909 S. Burt Wolbach, MD (1909-15) 1910 Frederick P. Gay, MD (1910-16) 1911 James Ewing, MD (1911-17) 1912 Harvey P. Gaylord, MD (1912-18) 1913 H. Gideon Wells, MD, PhD (1913-19) 1914 Richard Weil, MD (d.1917) 1915 No new appointments 1916 James B. Murphy, MD (1916-22) 1917 William H. Woglom, MD (1917-23) AACR Councilors and Directors Version: 7.30.20 SW 1918 Edwin R. LeCount, MD (1918-20) Robert P. Greenough, MD (1918-24) 1919 Willy Meyer, MD (1919-25) 1920 James Ewing, MD (1920-26) 1921 H. Gideon Wells, MD, PhD (1921-27) 1922 Frederick Prime, MD (1922-28) 1923 No new appointments 1924 Burton T. Simpson, MD (1924-30) 1925 Ward J. MacNeal, MD, PhD (1925-31) 1926 Millard C. Marsh, MS (1926-32) 1927 Elexious T. Bell, MD (1927-33) 1928 Aldred Scott Warthin, MD, PhD (d.1931) 1929 James Ewing, MD (1929-35) 1930 George H. A. Clowes, PhD (1930-36) 1931 Clarence C. Little, DSc (1931-37) 1932 Burton T. Simpson, MD (1932-38) 1933 Joseph McFarland, MD (1933-38) AACR Councilors and Directors Version: 7.30.20 SW 1934 James B. Murphy, MD (1934-9) 1935 Halsey J. Bagg, PhD (1935-39) 1936 Elexious T. Bell, MD (1936-39) 1937 William H. Woglom, MD (1937-39) 1938 James Ewing, MD (1938-39) George M. Smith, MD (1938-39) 1939 Howard B. Andervont, DSc (1939) George H. A. Clowes, PhD (1939) Carl Voegtlin, PhD (1939) 1940 Elexious T. Bell, MD (1940-41) George H. A. Clowes, PhD (1940-41) Clarence C. Little, DSc (1940-41) William H. Woglom, MD (1940-41) James Ewing, MD (1940-42) James B. Murphy, MD (1940-42) George M. Smith, MD (1940-42) Carl Voegtlin, PhD (1940-42) Howard B. Andervont, DSc (1940-1943) Halsey J. Bagg (1940-1943) Burton T. Simpson, MD (1940-43) Alphonse A. Thibaudeau, MD (1940-43) AACR Councilors and Directors Version: 7.30.20 SW DIRECTORS OF THE AACR BOARD (1941 TO DATE) Institution of origin listed is that which was provided at the time each board member was elected and is taken from the AACR member directory or, after 1963, from the ballot. Each listing represents what the institution was called at the time of the director’s election. Street addresses may indicate military service. 1941 Organizational Meeting Howard B. Andervont, DSc National Cancer Institute Bethesda, MD Halsey J. Bagg, PhD Memorial Hospital New York, NY Elexious T. Bell, MD University of Minnesota Medical School Minneapolis, MN George H.A. Clowes, PhD Eli Lilly and Company Indianapolis, IN Clarence C. Little, DSc Roscoe B. Jackson Memorial Laboratory Bar Harbor, ME James B. Murphy, MD Rockefeller Institute for Medical Research New York NY Burton T. Simpson. MD New York State Institute for the Study of Malignant Diseases Buffalo, NY George M. Smith, MD Pine Orchard, CT Alphonse A. Thibaudeau, MD New York State Institute for the Study of Malignant Diseases Buffalo, NY William H. Woglom, MD College of Physicians and Surgeons (Columbia) New York, NY AACR Councilors and Directors Version: 7.30.20 SW 1941-1944 Stanhope Bayne-Jones, MD Yale University School of Medicine New Haven, CT Clarence C. Little, DSc Roscoe B. Jackson Memorial Laboratory Bar Harbor, ME Shields Warren, MD New England Deaconess Hospital Boston, MA William H. Woglom, MD College of Physicians and Surgeons (Columbia) New York, NY 1942-1945 Ludvig Hektoen, MD, DSc Chicago Tumor Institute Chicago, IL James B. Murphy, MD Rockefeller Institute for Medical Research New York NY George M. Smith, MD Pine Orchard, CT Carl Voegtlin, PhD National Cancer Institute Bethesda, MD 1943-1946 Howard B. Andervont, DSc National Cancer Institute Bethesda, MD Edmund V. Cowdry, MD Barnard Free Skin and Cancer Hospital St. Louis, MO Edward A. Doisy, DSc, PhD St. Louis University School of Medicine St. Louis, MO AACR Councilors and Directors Version: 7.30.20 SW Howard C. Taylor, Jr., MD 842 Park Ave. New York, NY 1944-1947 Jacob Furth, MD Cornell University Medical College New York, NY Clarence C. Little, DSc Roscoe B. Jackson Memorial Laboratory Bar Harbor, ME Shields Warren, MD New England Deaconess Hospital Boston, MA William H. Woglom, MD 621 Tilden Avenue Teaneck, NJ 1945-1948 John T. Bittner, PhD University of Minnesota Medical School Minneapolis, MN William U. Gardner, PhD Yale University School of Medicine New Haven, CT Charles B. Huggins, MD University of Chicago Chicago, IL Murray J. Shear, PhD National Cancer Institute Bethesda, MD 1946-1949 Joseph C. Aub, MD Massachusetts General Hospital Boston, MA AACR Councilors and Directors Version: 7.30.20 SW Edmund V. Cowdry, PhD Barnard Free Skin and Cancer Hospital St. Louis, MO Edward A. Doisy, PhD St. Louis University School of Medicine St. Louis, MO Howard C. Taylor, Jr., MD 842 Park Ave. New York, NY 1947-1950 Austin M. Brues, MD University of Chicago Chicago, IL Jacob Furth, MD Cornell University Medical College New York, NY Clarence C. Little, DSc Roscoe B. Jackson Memorial Laboratory Bar Harbor, ME Shields Warren, MD New England Deaconess Hospital Boston, MA 1948-1951 John J. Bittner, PhD University of Minnesota Medical School Minneapolis, MN Charles W. Hooker, MD Yale University School of Medicine New Haven, CT Charles B. Huggins, MD University of Chicago Chicago, IL Balduin Lucké, MD University of Pennsylvania School of Medicine Philadelphia, PA AACR Councilors and Directors Version: 7.30.20 SW 1949-1952 Joseph C. Aub, MD Massachusetts General Hospital Boston, MA Edmund V. Cowdry, PhD Barnard Free Skin and Cancer Hospital St. Louis, MO Edward A. Doisy, PhD St. Louis University School of Medicine St. Louis, MO William U. Gardner, PhD Yale University School of Medicine New Haven, CT 1950-1953 Jacob Furth, MD Veterans Administration Hospital Dallas, TX George O. Gey, PhD Johns Hopkins Medical School Baltimore, MD Stanley P. Reimann, MD Lankenau Hospital Research Institute Philadelphia, PA Paul E. Steiner, MD, PhD University of Chicago Chicago, IL 1951-1954 Clarence C. Little, DSc Roscoe B. Jackson Memorial Laboratory Bar Harbor, ME Ira T. Nathanson, MD Massachusetts General Hospital Boston, MA Harold P. Rusch, MD McArdle Memorial Laboratory, University of Wisconsin Madison, WI AACR Councilors and Directors Version: 7.30.20 SW George W. Woolley, PhD Sloan-Kettering Institute New York, NY 1952-1955 Austin M. Brues, MD Argonne National Laboratory Chicago, IL Charles W. Hooker, PhD University of North Carolina Chapel Hill, NC G. Burroughs Mider, MD National Cancer Institute Bethesda, MD Fred W. Stewart, MD, PhD Memorial Hospital New York, NY 1953-1956 Howard B. Andervont, DSc National Cancer Institute Bethesda, MD Walter J. Burdette, PhD, MD Louisiana State University School of Medicine New Orleans, LA Alfred Gellhorn, MD College of Physicians and Surgeons Columbia University New York, NY Henry S. Kaplan, MD Stanford University School of Medicine San Francisco, CA 1954-1957 Roy Hertz, PhD, MD National Cancer Institute Bethesda, MD AACR Councilors and Directors Version: 7.30.20 SW David A. Karnofsky, MD Sloan Kettering Institute for Cancer Research New York, New York Albert Tannenbaum, MD Medical Research Institute Michael Reese Hospital Chicago, IL Paul C. Zamecnik, MD Massachusetts General Hospital Boston, MA 1955-1958 Sidney Farber, MD Children’s Cancer Research Foundation Boston, MA Jacob Furth, MD Children’s Cancer Research Foundation Boston, MA Van R. Potter, PhD McArdle Memorial Laboratory University of Wisconsin Madison, WI C. Chester Stock, PhD Sloan-Kettering Institute New York, NY 1956-1959 Harry S. N. Greene, MD Yale University School of Medicine New Haven, CT Walter E. Heston, PhD National Cancer Institute Bethesda, MD Lloyd W. Law, PhD National Cancer Institute Bethesda, MD AACR Councilors and Directors Version: 7.30.20 SW Harold L. Stewart, MD National Cancer Institute Bethesda, MD 1957-1960 Theodore S. Hauschka, PhD Roswell Park Memorial Institute Buffalo, NY Elizabeth C. Miller, PhD McArdle Memorial Laboratory University of Wisconsin Madison, WI Howard E. Skipper, PhD Southern Research Institute Birmingham, AL Sidney Weinhouse, PhD Institute for Cancer Research Philadelphia, PA 1958-1961 Walter J. Burdette, PhD, MD University of Utah College of Medicine Salt Lake City, UT Abraham Cantarow, MD Jefferson Medical College Philadelphia, PA Arnold M. Seligman, MD Sinai Hospital of Baltimore Baltimore, MD Murray J. Shear, PhD National Cancer Institute Bethesda, MD 1959-1962 Oscar Bodansky, MD Sloan-Kettering Institute for Cancer Research New York, NY AACR Councilors and Directors Version: 7.30.20 SW Thelma B. Dunn, MD National Cancer Institute Bethesda, MD Charles Heidelberger, PhD McArdle Memorial Laboratory University of Wisconsin Madison, WI George H. Hitchings, PhD Wellcome Research Laboratories Tuckahoe, NY 1960-1963 John J. Biesele, PhD University of Texas Austin, TX William U. Gardner, PhD Yale University School of Medicine New Haven, CT Alfred Gellhorn, MD Columbia University College of Physicians and Surgeons New York, NY Charles P. Leblond, MD, PhD McGill University Medical School Montreal, Quebec, Canada 1961-1964 Donald A. Clarke, PhD Sloan-Kettering Institute for Cancer Research New York, NY Paul Kotin, MD University of California Los Angeles School of Medicine Los Angeles, CA Arthur C. Upton, MD Oak Ridge National Laboratory Oak Ridge, TN Richard J. Winzler, PhD University of Illinois College of Medicine Chicago, IL AACR Councilors and Directors Version: 7.30.20 SW 1962-1965 George B. Brown, PhD Sloan-Kettering Institute for Cancer Research New York, NY Albert J.
Load more

Recommended publications
  • FELLOW, ONCOLOGY RESEARCH – Southern Research, Birmingham, AL SOUTHERN RESEARCH, a Nonprofit, Scientific Research Organization
    FELLOW, ONCOLOGY RESEARCH – Southern Research, Birmingham, AL SOUTHERN RESEARCH, a nonprofit, scientific research organization, is seeking an outstanding scientist for the position of Fellow in the field of Oncology The position is equivalent to the rank of Assistant, Associate or Full Professor in an academic institution (depending on the incumbent’s experience) and offers a unique opportunity to join the growing research team at Southern Research. Southern Research promotes a collaborative research environment to facilitate the multidisciplinary nature of drug discovery, accomplished internally through integration of basic biology, translational research, chemistry, and high-throughput screening, and also through its regional, national and international academic and industrial partnerships. The Oncology Department is focused on combining novel basic research and discovery to identify next generation cancer therapeutics. In contrast to traditional academic environments, Southern Research’s Oncology Department offers the opportunity for the individual to focus exclusively on engaging in research and professional development activities for advancement and development of new research ideas, support for the research team, and overall ability to make innovative advances in scholarly work portfolios. The Fellow of Oncology requires distinguished scholarship, including 10+ years of research experience in the field of oncology from any one of a number of concentrations, including cancer immunotherapy, cancer stem cells, cancer genomics, cancer pharmacogenomics, cancer microbiome, cancer pharmacology, genomic instability, or closely related area, and an ongoing extramurally-funded research program related to drug discovery. Southern Research desires a collegial, collaborative and outstanding scientist to cultivate mentorship and lead research within the Oncology Department. To be considered, applicants must: 1) possess a Ph.D., M.D.
    [Show full text]
  • Natural Resistance to Methotrexate in Human Melanomas
    0022-202X/80/7504-0357$02.00/0 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, 75:357-359, 1980 Vol. 75, No. 4 Copyright © 1980 by The Williams & Wilkins Co. Printed in U.S.A. Natural Resistance to Methotrexate in Human Melanomas DONALD W. KUFE, M .D ., MICHAEL M. WICK, M .D., PH.D., AND HERBERT T. ABELSON, M.D. Divisions of Pharmacology and Medical Onco logy (DWK and MM-w,J Sidney Farber Cancer Institute; Division of Pediatric Oncology (HTA) Sidney Farber Cancer Institute; and Departments of Medicine (DWK), Dermatology (MM"I¥,) and Pediatrics (HTA) Harvard Medical School, Boston, Massachusetts, U.S.A. Human melanomas are naturally resistant to metho­ resistant to the effects of MTX in vitro. The intracellular trexate (MTX). The mechanism of intrinsic drug resist­ uptake of MTX in these lines is comparable to other human ance has been explored in 3 melanoma cell lines not tumor cell lines. The mechanism of MTX resistance is attrib­ previously exposed to this agent. All 3 lines exhibited uted to elevated endogenous levels of DHFR. relative MTX resistance with ID5o values of greater than 1 fLM. Drug uptake studies were performed over an extra­ MATERIALS AND METHODS cellular concentration range of 0.1 to 10 ILM MTX. The Melanoma Growth Studies uptake was linear over the initial 10 min at all concen­ The growth characteristics of melanoma cell lines have been previ­ trations and subsequently reached plateau levels only at ously described [15]. Each line was established from metastatic mela­ the 10 ILM concentration. Lineweaver-Burke transfor­ noma and continues to have morphologic characteristics of melanin­ mations yielded apparent Km (uptake) values of 1.4 to 5 producing cells.
    [Show full text]
  • Awards, Appointments, Announcements
    NEWS Frederick W. Alt, Ph.D., a Howard biomedical science at the University of Awards, Hughes Medical Institute investigator at Texas Southwestern Medical Center at the Children’s Hospital of Boston, and Dallas, received the AACR Award for Appointments, the Charles A. Janeway Professor of Outstanding Achievement in Cancer Pediatrics and professor of genetics at Research. The award honors an accom- Announcements Harvard Medical School, received the plished young investigator in the field Vincent T. DeVita Jr., M.D., has 44th AACR-G.H.A. Clowes Memorial who is no more than 40 years old at the been named the Amy and Joseph Perella Award for his major discoveries involv- time the award is conferred. Wang was Professor of Medicine at Yale Univer- ing genomic stability and cancer. recognized for important discoveries sity in recognition of his contributions David Sidransky, M.D., was concerning the biochemical mecha- to cancer research and treatment. honored with the 28th AACR-Richard nisms of apoptosis. Director of Yale Cancer Center from & Hinda Rosenthal Foundation Award Paul Talalay, M.D., John Jacob Abel 1993 to 2003, DeVita currently serves for making a notable contribution to Distinguished Service Professor in the Downloaded from https://academic.oup.com/jnci/article/96/6/433/2606773 by guest on 03 October 2021 as chairman of the Yale Cancer Center improved clinical care in the field of Department of Pharmacology and Advisory Board and is a Yale University cancer. Sidransky is a professor of Molecular Sciences at the Johns Hopkins School of Medicine Professor of otolaryngology, oncology, urology, School of Medicine, was selected to Internal Medicine and Epidemiology genetics, pathology, and cellular and deliver the 9th AACR-DeWitt S.
    [Show full text]
  • Pathology in Focus
    PATHOLOGY IN FOCUS Vol 5 Issue 3 August 2011 Message from the Chair The start of the many faculty candidates will be several Department of Pathology Inside this issue: new school year visiting UAB and I hope that you will investigators are tentatively Faculty Profile: Dr. Hébert- 2-3 once again brings be able to attend as many candi- scheduled to move this fall into Magee many new faces date seminars as possible. renovated laboratory space in the to the Department Wallace Tumor Institute. These APC Teaching Awards 3-4 of Pathology. In A number of construction and new facilities will permit further Where Are They Now? 4 addition to the building renovation projects are expansion of cancer related re- Spotlight on Administration 5 annual influx of new residents, underway in the department and search in our department and help fellows and graduate students, several are nearing completion. I us to recruit additional outstanding New Changes in HIT 5-6 several new faculty members will am optimistic that by the time you clinicians and investigators to UAB. 6-7 From the Chief Residents be joining various divisions over read the next quarterly newsletter, From the Graduate Students 7-8 the next few months. Look for new the Anatomic Pathology Division faculty profiles in this and upcom- faculty, staff, and services cur- Best wishes, New Faculty Recruits 8 ing issues of our newsletter. Our rently housed in the Kracke Build- Kevin A. Roth, M.D., Ph.D. Pathology Grant Awards 9 aggressive recruitment strategy ing will all be moved to newly com- will continue through the fall as pleted facilities in PD6A.
    [Show full text]
  • Bio-Tech/Life Science Industry Profile
    ALABAMA’S BIO-INDUSTRY OVERVIEW Alabama’s multifaceted biosciences industry generates $7.3 billion in economic activity BIOSCIENCES annually while supporting 780 companies and nearly 48,000 direct and indirect jobs GENERATED across the state, according to an analysis by researchers at the University of Alabama. $7.3 BILLION Alabama’s biosciences sector is a robust combination of research institutions, labs, medical devices, innovative startups, pharmaceutical manufacturers, and more. IN ECONOMIC ACTIVITY BIO-INDUSTRY INNOVATION SUPPORTING Bioscience-Related U.S. Patents Bioscience-Related U.S. Patents 2014-2017 by Segment 2014-2017 780 53 Agricultural Chemicals COMPANIES 2014 161 Biochemistry 134 Bioinformatics & Health IT 9 2015 142 Biological Sampling & Analysis 42 Drugs & Pharmaceuticals 335 2016 159 Genetics 19 2017 141 Medical & Surgical Devices 240 Microbiology & Enzymes 37 Novel Plant Variants 14 Source: Bio.org, Alabama: Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018 www.bio.org/value-bioscience-innovation-growing-jobs-and- improving-quality-life-2018 Bioscience Academic R&D Expenditures 48,000 $ Millions FY 2016 DIRECT AND Health Sciences $373.3 INDIRECTJOBS Biological & Biomedical $152.1 ACROSS THE Sciences Agricultural STATE Sciences $72.0 Other Life $29.4 Sciences Bioengineering Source: BioAlabama / Biomedical $4.0 Engineering www.edpa.org / (205)943-4700 / ALABAMA’S BIO-INDUSTRY NATIONAL INSTITUTES OF HEALTH FUNDING $450,000 NIH Funding ($ thousands) Alabama’s Top NIH-funded Research Institutions $400,000 $350,000 University of Alabama at Birmingham $300,000 University of South Alabama $250,000 Auburn University $200,000 University of Alabama $150,000 Southern Research Institute $100,000 $294,964 $298,159 $280,132 $228,361 $350,735 $391,578 $253,111 HudsonAlpha Institute of Biotechnology $50,000 $254,389 Source: National Institutes of Health, NIH Awards by Location & $- Organization - U.S.
    [Show full text]
  • Peter Jeffrey Conn
    Peter Jeffrey Conn 2806 Acklen Ave. Nashville, TN 37212 Professional Address P. Jeffrey Conn, Ph.D. Lee E. Limbird Professor of Pharmacology Director, Vanderbilt Center for Neuroscience Drug Discovery Department of Pharmacology Vanderbilt University 2215 Garland Avenue 1215-D Light Hall Nashville, TN 37232-6600 Phone: (615) 936-2478 Fax: (615) 343-3088 E-mail: [email protected] Education 1977 – 1981 B.S. Lee University, Cleveland, Tennessee (Psychology) (Magna Cum Laude) 1981 – 1982 University of Cincinnati, Cincinnati, Ohio (Physiological Psychology) 1982 – 1986 Ph.D. Vanderbilt University, Nashville, Tennessee (Pharmacology) Professional Training and Experience 1986 Research Associate, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 1986 – 1988 Postdoctoral Fellow, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 1988 Visiting Lecturer, Yale College, Yale University, New Haven, CT 1988 – 1994 Assistant Professor, Department of Pharmacology, Emory University School of Medicine, Atlanta, GA P. Jeffrey Conn – Curriculum Vitae Page 2 1994 – 1999 Associate Professor, Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 1999 – 2000 Professor, Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 2000 – 2003 Senior Director and Head, Department of Neuroscience, Merck Research Laboratories, Merck and Company, West Point, PA 2000 – 2005 Adjunct Professor, Department of Pharmacology, Emory University School of Medicine, Atlanta,
    [Show full text]
  • A Visionary Scientist, Oncologist and Leader
    www.Genes&Cancer.com Genes & Cancer, Vol. 10 (5-6), 2019 John Mendelsohn: A visionary scientist, oncologist and leader Rakesh Kumar1,2,3, Ferid Murad4,5, Oliver Bogler6, Bert W. O’Malley7 and Gabriel N. Hortobagyi8 1 Cancer Biology Program, Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala, INDIA 2 Department of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, USA 3 Department of Medicine, Hematology-Oncology, Rutgers New Jersey Medical School, Newark, USA 4 Department of Medicine, Stanford University, Palo Alto, CA, USA 5 Palo Alto Veterans Institute for Research (Stanford Affiliated Hospital), Palo Alto, CA, USA 6 ECHO Institute, University of New Mexico, Albuquerque, USA 7 Department of Cellular and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA 8 Breast Medical Oncology, The University of Texas MD Anderson Cancer, Houston, Texas, USA Correspondence to: Rakesh Kumar, email: [email protected] Keywords: growth factor receptors; cetuximab; trastuzumab; targeted therapy; cancer centers Received: July 13, 2019 Accepted: July 19, 2019 Published: July 31, 2019 Copyright: Kumar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Dr. John Mendelsohn is credited for the concept of targeting the epidermal growth factor receptor (EGFR), providing the first evidence of anticancer activity of antagonist anti-EGFR mAb, and developing the Erbitux (Cetuximab) drug for cancer patients. During his professional journey, Dr. Mendelsohn also helped to build and elevate the status of three cancer cancers, all while touching the lives of cancer patients around the globe.
    [Show full text]
  • Antibiotic and Antibacterial Vaccine Development Services
    06/01/18 Antibiotic and Antibacterial Vaccine Development Services www.SouthernResearch.org/Drug-Development Contents Why choose Southern Research? ................................................................................................................. 4 in vitro Testing Services................................................................................................................................ 5 B0101 Minimum Inhibitory Concentration (MIC): ........................................................................................ 5 B0102 Minimum Bactericidal Concentration (MBC): .................................................................................... 5 B0103 Time-kill Assay: .................................................................................................................................. 5 B0104 Resistance Frequency Determination: ............................................................................................... 5 B0105 Post-antibiotic Effect (PAE): ............................................................................................................... 6 B0106 Serum and B0107 Protein Sensitivity: ............................................................................................... 6 B0108 Serum and B0109 Protein Binding: .................................................................................................... 6 B0110 Plasma and B0111 Microsome Stability: ........................................................................................... 6 B0112
    [Show full text]
  • Precision Cancer Medicine: Achievements and Prospects
    Precision Cancer Medicine: Achievements and Prospects John Mendelsohn, MD President Emeritus Tang Prize Award Ceremony September 22, 2018 Presented by Mien-Chie Hung, PhD Dr. John Mendelsohn with M.D. Anderson’s Hospital Education • Harvard College, Cambridge, MA, B.A., 1958, Biochemical Science • University of Glasgow, Glasgow, Scotland, Fulbright Scholar, 1959, Research in Molecular Biology • Harvard Medical School, M.D. 1963 Academic Administrative Appointments/Responsibilities •Founding Director of Cancer Center, University of California, San Diego, CA, 1976-85 •Chairman, Department of Medicine, Memorial Sloan- Kettering Cancer Center, New York, NY, 1985-96 •President, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1996- 2011 •Director, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2011-18 Scientific Achievements • First hypothesis, with Dr. Gordon Sato, that inhibition of EGF receptors and of a tyrosine kinase might be an effective anticancer treatment. 1980 • First creation of an anti-EGF receptor/anti-tyrosine kinase agent that blocked receptor kinase activation and inhibited cell growth. 1983-84 • First clinical trial with an agent targeting a growth factor receptor and a tyrosine kinase, demonstrating safety and feasibility. 1990 • First studies demonstrating mechanisms by which inhibition of EGF receptor tyrosine kinase inhibits cell proliferation and other cellular functions. 1996 • First clinical trial providing proof of concept that an antireceptor agent (Herceptin) used alone could produce a clinically useful response rate (10%) in patients. 1996 • First clinical trial demonstrating that addition of an EGF receptor inhibitor could overcome resistance to a chemotherapeutic agent (cisplatin in head and neck cancer).
    [Show full text]
  • Dana-Farber Facts
    2020FACTS Who We Are Dana-Farber Cancer Institute blends leading science and exceptional care into transformative medicine. Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and federally designated a Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries through- out the world. Since 1948, the Jimmy Fund has raised millions of dollars through thousands of community efforts to advance Dana-Farber’s lifesaving mission. EMPLOYEES Full-time 4,748 Part-time 483 Total 5,231 FACULTY MDs 317 PhDs 129 MD/PhDs 98 Total 544 All data in this publication is from fiscal year 2019. PATIENT CARE Dana-Farber cares for adults and children challenged with cancer, blood disorders, and related diseases. Our world-renowned specialists provide comprehensive and personalized care for each patient and support for their families. Our specialized treatment centers are staffed by teams of experts who work closely together to offer patients the latest therapies and strategies, including access to innovative clinical trials. Infusion Treatments 187,664 Outpatient MD Visits 359,519 New Patients 25,118 Unique Patients 74,084 REGISTERED NURSES Registered Nurses, Nurse Practitioners, Clinical Specialists, and Nurse Scientists 744 PATIENT SERVICES VOLUNTEERS Number of Volunteers 503 Combined Hours of Service 26,210 RESEARCH Dana-Farber remains true to its founder, Sidney Farber, MD, and his vision of a cancer center that is just as dedicated to discoveries in cancer research as it is to delivering expert, compassionate care. Through strategic investment in research, we support scientific leaders and young investigators, develop new therapies, and ensure a spirit of collaboration and innovation.
    [Show full text]
  • Improved Orthopedic Surgical Frame
    Improved Orthopedic Surgical Frame ALLIANCE FOR INNOVATIVE MEDICAL TECHNOLOGY – AIMTECH / TRAUMA Surgical retraction frame that can be quickly repositioned for procedures utilizing multiple surgical windows, especially for unstable pelvic fractures. Frame designed to be radio-lucent for use with X-ray procedures without needing to be disassembled or moved. ■■Technical Readiness Level ■■Inventors TRL 5 (Component validation in a relevant environment)— • Jason Lowe M.D., UAB Department Surgical frame made from carbon fiber components and of Orthopedic Surgery tested in a cadaver lab. • Alan Eberhardt, Ph.D., UAB Department ■■Competitive Advantages + Differentiation of Biomedical Engineering • Jason Lueck, Engineering, Southern Research Requires fewer surgical technicians to manually retract tissues, potentially reducing complications due to technician ■■Market Overview retraction error and fatigue. Reduced surgical time by Estimated 7M orthopedic fractures annually (US). Pelvic leaving frame in place during X-ray procedures. fractures represent 3%-6% of all fractures, and unstable ■■Intellectual Property Status fractures represent up to 20% of all pelvic fractures. ~63k. Patent Application WO 2016/611837 A1. PLEASE CONTACT Stacey Kelpke / Southern Research [email protected] / 205.581.2879 ABOUT SOUTHERN RESEARCH ABOUT UAB Founded in 1941 in Birmingham, Alabama, Southern Research is a scientific Known for its innovative and interdisciplinary approach to education at and engineering research organization that conducts preclinical drug both the graduate and undergraduate levels, the University of Alabama at discovery and development, advanced engineering research in materials, Birmingham is an internationally renowned research university and academic systems development, and energy and environmental technologies medical center, as well as Alabama’s largest employer, with some 23,000 research.
    [Show full text]
  • More Than Courage
    More than Courage DANA-FARBER CANCER INSTITUTE It takes more than courage to beat cancer ® What does it take to beat cancer? It takes courage, yes, and that is just the beginning. It takes world-class researchers, doctors, and technologically advanced facilities. It takes teams of dedicated professionals who offer compassionate care every day, gathering insight to inform and advance treatments for everyone. It takes focus and determination— people committed to taking the bold steps necessary to advance the cause. It also takes you. Illustrations throughout this publication represent Dana-Farber’s industry-leading science, technology, and patient care. “ I have never accepted the incurability of cancer.” — Sidney Farber, MD Founder, Dana-Farber Cancer Institute Rooted in innovation and leadership, our history remains a powerful source of motivation. The work that began in a small basement laboratory in 1947 in Boston has evolved and grown over time, and it has made Dana-Farber one of the most prestigious cancer centers in the world. Today, Dana-Farber embodies the very essence of our founder’s pioneering vision: one of leadership grounded in a commitment to research and compassion, driven to provide expert care to adults and children with cancer. It takes Experience dana-farber.org | jimmyfund.org 3 Experience Dana-Farber is a global leader in cancer A Revolutionary research and patient care. 396,000+ Vision Patient visits and infusions, annually Dana-Farber founder Sidney Farber, MD, is the father of modern chemotherapy. Founding the Institute in 1947 in Boston, Dr. Farber and his team dedicated their work to providing compassionate, state-of-the-art treatment for cancer patients, 4,500+ while researching cures of the future.
    [Show full text]